S-Adenosyl-L-methionine augmentation in patients with stage II treatment-resistant major depressive disorder: An open label, fixed dose, single-blind Study

The Scientific World Journal

Volumn 2013, Issue , 2013, Pages

  De Berardis, Domenico ^a,b   Marini, Stefano ^a,b   Serroni, Nicola ^b   Rapini, Gabriella ^b   Iasevoli, Felice ^c   Valchera, Alessandro ^d   Signorelli, Maria ^e   Aguglia, Eugenio ^e   Perna, Giampaolo ^f,g,h   Salone, Anatolia ^a   Di Iorio, Giuseppe ^a   Martinotti, Giovanni ^a   Di Giannantonio, Massimo ^a  

^a UNIVERSITY OF CHIETI   (Italy)

^b G Mazzini Hospital   (Italy)

^c UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^d Hermanas Hospitalarias   (Italy)

^e UNIVERSITY OF CATANIA   (Italy)

^f Department of Clinical Neurosciences   (Italy)

^g UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^h MAASTRICHT UNIVERSITY   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

AGOMELATINE; AMFEBUTAMONE; DULOXETINE; ESCITALOPRAM; MIRTAZAPINE; PLACEBO; S ADENOSYLMETHIONINE; SERTRALINE; VENLAFAXINE; ADENOSINE; ANTIDEPRESSANT AGENT; DRUG DERIVATIVE; ETHIONINE; S ADENOSYLETHIONINE; S-ADENOSYLETHIONINE;

ADULT; ARTICLE; CLINICAL GLOBAL IMPRESSION SCALE; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; HAMILTON SCALE; HUMAN; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; REMISSION; SHEEHAN DISABILITY SCALE; SINGLE BLIND PROCEDURE; SNAITH HAMILTON PLEASURE SCALE; TREATMENT DURATION; TREATMENT RESPONSE; CLINICAL TRIAL; DRUG COMBINATION; PSYCHOLOGICAL ASPECT; TREATMENT OUTCOME;

ADENOSINE; ADULT; ANTIDEPRESSIVE AGENTS; DEPRESSIVE DISORDER, MAJOR; DRUG THERAPY, COMBINATION; ETHIONINE; FEMALE; HUMANS; MALE; SINGLE-BLIND METHOD; TREATMENT OUTCOME;

EID: 84878662972     PISSN: None     EISSN: 1537744X     Source Type: Journal    
DOI: 10.1155/2013/204649     Document Type: Article

References (22)

1. Kessler R. C., Berglund P., Demler O., Jin R., Koretz D., Merikangas K. R., Rush A. J., Walters E. E., Wang P. S., The epidemiology of major depressive disorder: results from the national comorbidity survey replication (NCS-R). The Journal of the American Medical Association 2003 289 23 3095 3105 2-s2.0-0037831023 10.1001/jama.289.23.3095 (Pubitemid 37432885)
2. Fava M., Diagnosis and definition of treatment-resistant depression. Biological Psychiatry 2003 53 8 649 659 10.1016/S0006-3223(03)00231-2 (Pubitemid 39658481)
3. Keller M. B., Issues in treatment-resistant depression. The Journal of Clinical Psychiatry 2005 66 supplement 8 5 12 10.4088/JCP.v66n0101 (Pubitemid 43004170)
4. Thase M. E., Rush A. J., Bloom F. E., Kupfer D. J., Treatment-resistant depression. Psychopharmacology: The Fourth Generation of Progress 1995 New York, NY, USA Raven Press 1081 1097
5. Hori H., Kunugi H., The efficacy of pramipexole, a dopamine receptor agonist, as an adjunctive treatment in treatment-resistant depression: an open-label trial. The Scientific World Journal 2012 2012 8 372474 10.1100/2012/372474
6. Lieber C. S., S-adenosyl-L-methionine: Its role in the treatment of liver disorders. The American Journal of Clinical Nutrition 2002 76 5 1183S 1187S 2-s2.0-0036829222 (Pubitemid 35244699)
7. Clarke S., Banfield K., Carmel R., Jacobsen D., S-adenosylmethionine- dependent methyltransferases. Homocysteine in Health and Disease 2001 Cambridge, UK Cambridge University Press 63 78
8. Finkelstein J. D., Kyle W. E., Martin J. J., Pick A. M., Activation of cystathionine synthase by adenosylmethionine and adenosylethionine. Biochemical and Biophysical Research Communications 1975 66 1 81 87 2-s2.0-0016837233
9. Cravo M. L., Gloria L. M., Selhub J., Nadeau M. R., Camilo M. E., Resende M. P., Cardoso J. N., Leitao C. N., Mira F. C., Hyperhomocysteinemia in chronic alcoholism: correlation with folate, vitamin B-12, and vitamin B-6 status. The American Journal of Clinical Nutrition 1996 63 2 220 224 2-s2.0-0030066048 (Pubitemid 26036243)
10. Bottiglieri T., Laundy M., Martin R., S-adenosylmethionine influences monoamine metabolism. The Lancet 1984 2 8396 224 2-s2.0-0021242051 (Pubitemid 14094980)
11. Papakostas G. I., Cassiello C. F., Iovieno N., Folates and S-adenosylmethionine for major depressive disorder. Canadian Journal of Psychiatry 2012 57 7 406 413
12. Alpert J. E., Papakostas G., Mischoulon D., Worthington J. J., Petersen T., Mahal Y., Burns A., Bottiglieri T., Nierenberg A. A., Fava M., S-adenosyl-L-methionine (SAMe) as an adjunct for resistant major depressive disorder: an open trial following partial or nonresponse to selective serotonin reuptake inhibitors or venlafaxine. Journal of Clinical Psychopharmacology 2004 24 6 661 664 2-s2.0-8744287602 10.1097/01.jcp.0000145339.45794.cd (Pubitemid 39518665)
13. Papakostas G. I., Mischoulon D., Shyu I., Alpert J. E., Fava M., S-adenosyl methionine (SAMe) augmentation of serotonin reuptake inhibitors for antidepressant nonresponders with major depressive disorder: a double-blind, randomized clinical trial. The American Journal of Psychiatry 2010 167 8 942 948 2-s2.0-77955360283 10.1176/appi.ajp.2009.09081198
14. Berlanga C., Ortega-Soto H. A., Ontiveros M., Senties H., Efficacy of S-adenosyl-L-methionine in speeding the onset of action of imipramine. Psychiatry Research 1992 44 3 257 262 2-s2.0-0027080912 10.1016/0165-1781(92) 90029-3 (Pubitemid 23036978)
15. First M. B., Spitzer R. L., Gibbon M., Williams J. B. W., Structured Clinical Interview for DSM-IV-TR Axis I Disorders 2002 New York, NY, USA Biometrics Research Research Version (SCID-I/P)
16. Hamilton M., A rating scale for depression. Journal of Neurology, Neurosurgery, and Psychiatry 1960 23 56 62 2-s2.0-72949151592
17. Guy W., Clinical Global Impression, ECDEU Assessment Manual for Psychopharmacology 1976 Rockville, Md, USA National Institute of Mental Health
18. Snaith R. P., Hamilton M., Morley S., Humayan A., Hargreaves D., Trigwell P., A scale for the assessment of hedonic tone. The Snaith-Hamilton pleasure scale. The British Journal of Psychiatry 1995 167 99 103 2-s2.0-0029552524 (Pubitemid 26124582)
19. Ballenger J. C., Clinical guidelines for establishing remission in patients with depression and anxiety. Journal of Clinical Psychiatry 1999 60 29 34 10.4088/JCP.v60n0106 (Pubitemid 30107953)
20. Fava M., Rush A. J., Wisniewski S. R., Nierenberg A. A., Alpert J. E., McGrath P. J., Thase M. E., Warden D., Biggs M., Luther J. F., Niederehe G., Ritz L., Trivedi M. H., A comparison of mirtazapine and nortriptyline following two consecutive failed medication treatments for depressed outpatients: a STAR D report. The American Journal of Psychiatry 2006 163 7 1161 1172 2-s2.0-33746928782 10.1176/appi.ajp.163.7.1161 (Pubitemid 44464443)
21. Fang Y., Yuan C., Xu Y., Chen J., Wu Z., Cao L., Yi Z., Hong W., Wang Y., Jiang K., Cui X., Calabrese J. R., Gao K., A pilot study of the efficacy and safety of paroxetine augmented with risperidone, valproate, buspirone, trazodone, or thyroid hormone in adult Chinese patients with treatment-resistant major depression. Journal of Clinical Psychopharmacology 2011 31 5 638 642 10.1097/JCP.0b013e31822bb1d9
22. Gambi F., de Berardis D., Campanella D., Carano A., Sepede G., Salini G., Mezzano D., Cicconetti A., Penna L., Salerno R. M., Ferro F. M., Mirtazapine treatment of generalized anxiety disorder: a fixed dose, open label study. Journal of Psychopharmacology 2005 19 5 483 487 2-s2.0-25844490851 10.1177/0269881105056527 (Pubitemid 41392302)